Arena Pharmaceuticals

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. The Company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1977
Size (employees)
106 (est)
Arena Pharmaceuticals was founded in 1977 and is headquartered in San Diego, US

Arena Pharmaceuticals Office Locations

Arena Pharmaceuticals has offices in San Diego and Zofingen
San Diego, US (HQ)
6154 Nancy Ridge Drive
Zofingen, CH
4 Untere Brühlstrasse

Arena Pharmaceuticals Financials and Metrics

Arena Pharmaceuticals Financials

Arena Pharmaceuticals's revenue was reported to be $124 m in FY, 2016
USD

Revenue (Q2, 2017)

6.5 m

Gross profit (Q2, 2017)

5 m

Gross profit margin (Q2, 2017), %

77%

Net income (Q2, 2017)

(23.6 m)

EBIT (Q2, 2017)

(21.2 m)

Market capitalization (13-Dec-2017)

1.2 b

Cash (30-Jun-2017)

130.8 m
Arena Pharmaceuticals's current market capitalization is $1.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

81.4 m37 m38.3 m124 m

Revenue growth, %

(55%)4%223%

Cost of goods sold

1.8 m6.4 m8.6 m9.3 m

Gross profit

79.6 m30.6 m29.7 m114.7 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

3.6 m6.8 m12.8 m8.2 m12.3 m9.2 m9.1 m9.8 m9.5 m19.2 m6.6 m6.5 m

Cost of goods sold

460 k831 k1.5 m1.8 m3.2 m1.3 m1.6 m2.4 m851 k882 k2.5 m1.5 m

Gross profit

3.1 m6 m11.3 m6.4 m9.1 m7.9 m7.5 m7.4 m8.7 m18.4 m4.1 m5 m

Gross profit Margin, %

87%88%89%79%74%86%82%75%91%95%62%77%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

221.9 m163.2 m156.2 m90.7 m

Accounts Receivable

10.6 m3.7 m4.9 m20.2 m

Inventories

3.6 m4.1 m4.2 m6.7 m

Current Assets

248.8 m181.9 m174.8 m119.9 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

180.7 m203.3 m200.8 m188.3 m241 m216.7 m181.3 m139.5 m122 m101.6 m79.5 m130.8 m

Accounts Receivable

12.4 m1.6 m7.4 m2.9 m12.2 m4.2 m3.5 m6.2 m3.3 m18.3 m1.7 m2.4 m

Inventories

10 m11.9 m12.6 m11.9 m11.4 m11 m10.2 m9.1 m9.5 m10.2 m7.1 m7.1 m

Current Assets

206.6 m276.4 m243.7 m209.1 m268.6 m236 m200.2 m160.1 m139.8 m134.9 m92.3 m143.6 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(19.4 m)(60.5 m)(108 m)(22.9 m)

Depreciation and Amortization

7.7 m8.7 m9.8 m9.1 m

Accounts Receivable

(4.5 m)6.4 m(1.4 m)(15.9 m)

Inventories

(6.1 m)870 k1.9 m3.2 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(17.2 m)(25.3 m)7.5 m(10.7 m)(24.3 m)(26.8 m)(26.4 m)(21.5 m)(27.2 m)(12.5 m)(22.5 m)

Accounts Receivable

7.4 m2.9 m12.2 m4.2 m3.5 m6.2 m3.3 m18.3 m1.7 m

Inventories

12.6 m11.9 m11.4 m11 m10.2 m9.1 m9.5 m10.2 m7.1 m
Y, 2017

Financial Leverage

2.3 x
Show all financial metrics

Arena Pharmaceuticals Market Value History

Arena Pharmaceuticals's Web-traffic and Trends

Arena Pharmaceuticals Company Life and Culture

You may also be interested in